Nom du produit:(S)-2-(1,4-Dibenzylpiperazin-2-yl)acetonitrile

IUPAC Name:2-[(2S)-1,4-dibenzylpiperazin-2-yl]acetonitrile

CAS:2225787-92-6
Formule moléculaire:C20H23N3
Pureté:95%+
Numéro de catalogue:CM335976
Poids moléculaire:305.42

Unité d'emballage Stock disponible Prix($) Quantité
CM335976-100mg in stock Ʃƅş
CM335976-250mg in stock Ǡƅŭ
CM335976-1g 1-2 Weeks ŭșȋŭ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:2225787-92-6
Formule moléculaire:C20H23N3
Point de fusion:-
Code SMILES:N#CC[C@@H]1N(CC2=CC=CC=C2)CCN(CC3=CC=CC=C3)C1
Densité:
Numéro de catalogue:CM335976
Poids moléculaire:305.42
Point d'ébullition:
N° Mdl:
Stockage:2-8°C

Category Infos

Piperazines
Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.
Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Adagrasib
Jan. 10, 2024, EC approves KRAZATI (adagrasib) as a targeted treatment option for patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.
Adagrasib is an orally available, potent, irreversible, small molecule inhibitor of KRAS G12C mutant isoform for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation. Adagrasib covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state, thereby preventing downstream signalling without affecting wild-type KRAS protein.

Related Products